ArticleAlimentary pharmacology & therapeutics2022
Validation of the Achalasia Patient-Reported Outcomes Questionnaire.
Article in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Symptom duration is associated with esophageal remodeling in achalasia treated by peroral endoscopic myotomy.Scientific reports · 2026Observational
- Effects of body position on high-resolution manometry parameters and their correlations with symptoms.Journal of clinical biochemistry and nutrition · 2026Article
- Translation and cross-sectional validation of the achalasia patient reported outcomes questionnaire in a Dutch cohort.BMC gastroenterology · 2026Article
- Saudi Gastroenterology Association (SGA) clinical care pathway and standards of care for peroral endoscopic myotomy (POEM) in achalasia.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Mid-term outcomes of the patients of achalasia cardia undergoing laparoscopic Heller's myotomy with angle of his accentuation versus laparoscopic Heller's myotomy with Toupet's fundoplication.Surgical endoscopy · 2025Article
- Patient-Reported Outcome Measures in Benign Esophageal Disorders.The American journal of gastroenterology · 2025Review
- Real-life management of nonobstructive esophageal dysphagia: analysis of a prospective multicentric Portuguese cohort.Therapeutic advances in gastroenterology · 2025Article
- Novel scale for evaluating the therapeutic efficacy of per-oral endoscopic myotomy in achalasia.Journal of gastroenterology · 2024Article
- The role of hypervigilance in chronic esophageal diseases: a scoping review.Translational gastroenterology and hepatology · 2024Article
- Validation of the Achalasia Patient-Reported Outcomes Questionnaire.Alimentary pharmacology & therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAchalasia is a debilitating major motor disorder of the oesophagus. Hypervigilance and symptom-specific anxiety substantially impact dysphagia symptom reporting, and quality of life is a critical patient outcome. Earlier achalasia symptom scales did not consider these constructs in their psychometric development.
aimTo develop a new symptom measure, the Achalasia Patient-Reported Outcomes (APRO) Questionnaire
methodsFour gastroenterologists with achalasia expertise generated preliminary items. Patients reviewed items via cognitive interviews. Patients undergoing high-resolution manometry completed the APRO with Oesophageal Hypervigilance and Anxiety Scale, Northwestern Oesophageal Quality of Life Scale, and three measures of reflux and dysphagia. Full APRO psychometric assessment (reliability, validity, factor structure) was done. Cluster analysis evaluated APRO + symptom-anxiety/hypervigilance patient phenotypes.
resultsWe included 961 patients with normal motility and 296 with achalasia. The APRO yielded three subscales: dysphagia, reflux, chest pain with two items for weight change and diet modifications. Reliability and validity were excellent. Twenty-five percent of achalasia patients may have high levels of anxiety/hypervigilance despite low symptoms, while 8% may report severe symptoms with low anxiety/hypervigilance. The APRO significantly predicted quality of life, but less cognitive-affective processes.
conclusionsThe APRO is a reliable and valid measure of achalasia symptoms that addresses the limitations of existing questionnaires. Symptom anxiety and hypervigilance moderate the relationship between APRO and quality of life; 33% of patients with achalasia exhibit concerning patterns in symptom severity, anxiety and hypervigilance that may contribute to poorer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.